Cardiology

Le discusses the AHA/ACC clinical guidelines for the management of dyslipidemia, highlighting PREVENT and a renewed focus on Lp(a).

This conference preview with Kathryn Berlacher, MD, MS, and Kristen Campbell, PharmD, highlights the top 6 trials to watch at ACC 2026.

An audio recap of the top 5 stories in healthcare news from the week of 03/02-03/08.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new trial data, in this week’s essential news roundup.

Lala discusses ongoing challenges in the HF treatment cascade, highlighting widespread misunderstandings among patients and the issue of extreme pill burden.

Lala discusses the ethical, medical, and practical concerns surrounding xenotransplantation of pig hearts – and how they should be addressed in clinical research.

Kadosh and Gorodeski discuss the value of including non-specialists in HF care and the challenges of prescribing 4 pills in a time of increasing medical distrust.

Satish discusses his recent study highlighting significant increases in first AMI in-hospital mortality among young adults, particularly in women.

The FDA accepted Mineralys Therapeutics’ NDA for lorundrostat in hypertension, but the selective aldosterone synthase inhibitor fell short in a phase 2 obstructive sleep apnea trial.

Kadosh and Gorodeski discuss 2 of the major challenges facing both patients and clinicians dealing with HF and how to address them.

Stay updated with the latest healthcare breakthroughs, FDA actions, and new trial data, in this week’s essential news roundup.

Maddox discusses the AHA’s recent statement indicating that, should current trends continue, 6 in 10 US women will have cardiovascular disease by 2050.

In the final part of this 6-part HCPLive Special Report, experts discuss the recently released HFSA/AAHFN joint statement on tech integration in heart failure care.

In part 5 of this 6-part HCPLive Special Report, experts discuss the recently released HFSA/AAHFN joint statement on tech integration in heart failure care.

In part 4 of this 6-part HCPLive Special Report, experts discuss the recently released HFSA/AAHFN joint statement on tech integration in heart failure care.

In part 3 of this 6-part HCPLive Special Report, experts discuss the recently released HFSA/AAHFN joint statement on tech integration in heart failure care.

In part 2 of this 6-part HCPLive Special Report, experts discuss the recently released HFSA/AAHFN joint statement on tech integration in heart failure care.

In part 1 of this 6-part HCPLive Special Report, experts discuss the recently released HFSA/AAHFN joint statement on tech integration in heart failure care.

Catch up with FDA decisions, key trial results, and more.

Parent company United Therapeutics announced ralinepag’s substantial reduction in worsening clinical events, as well as improving 6MWD and NT-proBNP.

Anadani discusses a recent study highlighting the myriad contributing factors in the steadily increasing risk of maternal stroke across the country.

Bhatt discusses a recent study from GSK highlighting AREXVY’s efficacy in lowering major adverse cardiovascular events.

Ross Milner, MD, discusses rising vascular complexity, advanced imaging and AI, and the team-based strategies driving durable aortic and limb salvage outcomes.

Manreet Kanwar, MD, outlines advances in heart failure care, rising medication complexity, and the need for integrated, patient-centered systems.

Pressman discusses his recent study highlighting the interplay between right ventricular end-diastolic volume and ejection fraction and the left ventricle’s health.